• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

透析患者多重用药的管理

Management of Polypharmacy in Dialysis Patients.

作者信息

St Peter Wendy L

机构信息

College of Pharmacy, University of Minnesota, Minneapolis, Minnesota.

Chronic Disease Research Group, Minneapolis Medical Research Foundation, Minneapolis, Minnesota.

出版信息

Semin Dial. 2015 Jul-Aug;28(4):427-32. doi: 10.1111/sdi.12377. Epub 2015 Apr 9.

DOI:10.1111/sdi.12377
PMID:25864928
Abstract

Most patients receiving dialysis have other common chronic conditions in addition to end-stage renal disease, including hypertension, diabetes, cardiovascular disease, and mineral and bone disorder, all of which require long-term medication management. Dialysis patients take an average of 10-12 prescribed and over-the-counter medications from an average of 4.7 prescribers, and an average of 19 pills per day. Thus, reducing polypharmacy is not adequate as a medication therapy goal for these patients. Instead, the dialysis community should focus on ensuring that all patients receive medications that are appropriate, effective, safe and convenient. Barriers to this include a fragmented health care system with inadequate communication between multiple prescribers and pharmacies, and frequent care transitions between ambulatory care sites (dialysis centre, ambulatory primary care practice, ambulatory specialty practice) and the hospital, skilled nursing facility or long-term care facility. Three distinct processes are necessary to prevent and solve the resultant medication-related problems (and reduce polypharmacy). These are medication reconciliation (creating an accurate medication list that reflects all medications the patients is taking and how they are being taken), medication review (evaluating the list for appropriateness, effectiveness, safety and convenience in conjunction with the patient's health status), and ongoing patient-centred medication therapy management (e.g., developing treatment plans centred on each patient's medication-related goals). A team approach including pharmacists as part of the dialysis team with the dialysis facility as the primary medication home is needed.

摘要

大多数接受透析的患者除了患有终末期肾病外,还患有其他常见的慢性病,包括高血压、糖尿病、心血管疾病以及矿物质和骨代谢紊乱,所有这些都需要长期的药物管理。透析患者平均从4.7名开处方的医生那里获取10 - 12种处方药和非处方药,平均每天服用19片药。因此,减少多重用药作为这些患者的药物治疗目标是不够的。相反,透析领域应专注于确保所有患者都能获得合适、有效、安全且方便的药物。这方面的障碍包括医疗保健系统碎片化,多个开处方的医生和药房之间沟通不足,以及在门诊护理场所(透析中心、门诊初级护理机构、门诊专科机构)与医院、熟练护理机构或长期护理机构之间频繁的护理转接。预防和解决由此产生的药物相关问题(并减少多重用药)需要三个不同的过程。这些过程分别是药物重整(创建一份准确的用药清单,反映患者正在服用的所有药物及其服用方式)、药物审查(结合患者的健康状况评估清单在适用性、有效性、安全性和便利性方面的情况)以及持续的以患者为中心的药物治疗管理(例如,制定以每个患者的药物相关目标为中心的治疗计划)。需要一种团队方法,将药剂师纳入透析团队,以透析机构作为主要的药物管理场所。

相似文献

1
Management of Polypharmacy in Dialysis Patients.透析患者多重用药的管理
Semin Dial. 2015 Jul-Aug;28(4):427-32. doi: 10.1111/sdi.12377. Epub 2015 Apr 9.
2
Improving medication safety in chronic kidney disease patients on dialysis through medication reconciliation.通过用药重整改善透析慢性肾脏病患者的用药安全。
Adv Chronic Kidney Dis. 2010 Sep;17(5):413-9. doi: 10.1053/j.ackd.2010.06.001.
3
Medication reconciliation and therapy management in dialysis-dependent patients: need for a systematic approach.透析依赖患者的药物重整和治疗管理:需要系统方法。
Clin J Am Soc Nephrol. 2013 Nov;8(11):1988-99. doi: 10.2215/CJN.01420213. Epub 2013 Aug 29.
4
Medication Reconciliation: The Foundation of Medication Safety for Patients Requiring Dialysis.药物重整:透析患者用药安全的基础。
Am J Kidney Dis. 2020 Dec;76(6):868-876. doi: 10.1053/j.ajkd.2020.07.021. Epub 2020 Sep 10.
5
Appendix to dialysis centre guidelines: recommendations for the relationship between outpatient haemodialysis centres and reference hospitals. Opinions from the Outpatient Dialysis Group. Grupo de Trabajo de Hemodiálisis Extrahospitalaria.附录:透析中心指南:门诊血液透析中心与参考医院之间关系的建议。来自门诊透析组的意见。
Nefrologia. 2011;31(6):664-9. doi: 10.3265/Nefrologia.pre2011.Oct.11001.
6
Adherence to multiple, prescribed medications in diabetic kidney disease: A qualitative study of consumers' and health professionals' perspectives.糖尿病肾病患者对多种处方药物的依从性:一项关于消费者和健康专业人员观点的定性研究。
Int J Nurs Stud. 2008 Dec;45(12):1742-56. doi: 10.1016/j.ijnurstu.2008.07.002. Epub 2008 Aug 13.
7
The delicate balance of keeping it all together: Using social capital to manage multiple medications for patients on dialysis.维持整体平衡:利用社会资本为透析患者管理多种药物治疗
Res Social Adm Pharm. 2017 Jul-Aug;13(4):738-745. doi: 10.1016/j.sapharm.2016.07.008. Epub 2016 Aug 3.
8
Assessment of a safety enhancement to the hospital medication reconciliation process for elderly patients.对老年患者医院用药核对流程安全强化措施的评估。
Am J Geriatr Pharmacother. 2010 Apr;8(2):127-35. doi: 10.1016/j.amjopharm.2010.03.004.
9
Medication management in dialysis: Barriers and strategies.透析中的药物管理:障碍与策略。
Semin Dial. 2020 Nov;33(6):449-456. doi: 10.1111/sdi.12935. Epub 2020 Nov 19.
10
Polypharmacy in hospitalized older adult cancer patients: experience from a prospective, observational study of an oncology-acute care for elders unit.老年住院癌症患者的多重用药:一项针对老年肿瘤急症护理单元的前瞻性观察研究经验
Am J Geriatr Pharmacother. 2009 Jun;7(3):151-8. doi: 10.1016/j.amjopharm.2009.05.002.

引用本文的文献

1
Medication Burden and Adverse Cardiovascular Events and Death in Patients Treated with Maintenance Hemodialysis: A Nationwide Cohort Study.维持性血液透析患者的用药负担、心血管不良事件及死亡:一项全国性队列研究
Clin J Am Soc Nephrol. 2025 Jan 1;20(1):72-80. doi: 10.2215/CJN.0000000000000570. Epub 2024 Sep 20.
2
Efficacy and safety of intradialytic parenteral nutrition using ENEFLUID® in malnourished patients receiving maintenance hemodialysis: An exploratory, multicenter, randomized, open-label study.使用ENEFLUID®进行透析期间胃肠外营养对维持性血液透析的营养不良患者的疗效和安全性:一项探索性、多中心、随机、开放标签研究。
PLoS One. 2024 Dec 12;19(12):e0311671. doi: 10.1371/journal.pone.0311671. eCollection 2024.
3
Prescribing patterns and medication costs in patients on maintenance haemodialysis and peritoneal dialysis.
维持性血液透析和腹膜透析患者的用药模式及药物费用
Nephrol Dial Transplant. 2025 Feb 4;40(2):360-370. doi: 10.1093/ndt/gfae154.
4
Prescription and Dispensation of QT-Prolonging Medications in Individuals Receiving Hemodialysis.接受血液透析个体的 QT 延长药物的处方与调配。
JAMA Netw Open. 2024 Apr 1;7(4):e248732. doi: 10.1001/jamanetworkopen.2024.8732.
5
Determination of drug-related problems according to PAIR criteria in dialysis patients: a cross-sectional study in tertiary care hospital.根据 PAIR 标准确定透析患者的药物相关问题:三级保健医院的横断面研究。
BMC Pharmacol Toxicol. 2024 Apr 18;25(1):28. doi: 10.1186/s40360-024-00754-6.
6
Long-term safety and decrease of pill burden by tenapanor therapy: a phase 3 open-label study in hemodialysis patients with hyperphosphatemia.长期应用替班那诺治疗血液透析高磷血症患者的安全性和减少药物负担:一项 3 期开放性研究。
Sci Rep. 2023 Nov 4;13(1):19100. doi: 10.1038/s41598-023-45080-9.
7
The Future of Drug Delivery.药物递送的未来。
Chem Mater. 2023 Jan 24;35(2):359-363. doi: 10.1021/acs.chemmater.2c03003.
8
The Value of Pharmacogenomics for White and Indigenous Americans after Kidney Transplantation.肾移植后药物基因组学对美国白人和原住民的价值。
Pharmacy (Basel). 2023 Aug 8;11(4):125. doi: 10.3390/pharmacy11040125.
9
QT-Prolonging Antibiotics, Serum-to-Dialysate Potassium Gradient, and Risk of Sudden Cardiac Death Among Patients Receiving Maintenance Hemodialysis.接受维持性血液透析患者中,延长QT间期的抗生素、血清与透析液的钾梯度及心源性猝死风险
Kidney Med. 2023 Feb 15;5(5):100618. doi: 10.1016/j.xkme.2023.100618. eCollection 2023 May.
10
Balancing Risk and Uncertain Benefit in Pharmacotherapy for Pain in Kidney Transplant Recipients.肾移植受者疼痛药物治疗中风险与不确定获益的权衡
Clin J Am Soc Nephrol. 2023 Jan 1;18(1):3-4. doi: 10.2215/CJN.0000000000000031.